Stock

Kroger to pay $110 million to resolve Kentucky lawsuit over opioid epidemic

By Nate Raymond (NS:RYMD)

(Reuters) -Kroger has agreed to pay $110 million to resolve a lawsuit by the state of Kentucky alleging the supermarket chain’s pharmacies helped fuel a deadly opioid epidemic by flooding its communities with hundreds of millions of doses of addictive painkillers.

The settlement was announced on Thursday by Kentucky Attorney General Russell Coleman, whose state had opted to not participate in a broader $1.4-billion deal Kroger (NYSE:KR) finalized last year that resolved similar claims by 30 states as well as counties, municipalities and Native American tribes.

In a lawsuit filed in state court in February, Coleman had alleged that Kroger’s more than 100 Kentucky pharmacies had been responsible for over 11% of all opioid pills dispensed in the state from 2006 to 2019, or about 444 million opioid doses. 

The lawsuit alleged Kroger should have known based on the suspiciously high numbers and other red flags that the drugs were being diverted for illicit purposes, and should have taken measures to stop shipments and refuse to fill suspicious prescriptions.

Instead, Kroger continued to ship massive quantities of opioids throughout the state, failed to report suspicious orders to authorities and continued to dispense addictive drugs at “alarming” rates in Kentucky, which was hard-hit by the drug-addiction epidemic, according to the lawsuit.

“This massive grocery chain that asked for our trust and our business allowed the fire of addiction to spread across the commonwealth, leaving pain and leaving so much brokenness in its aftermath,” Coleman said at a press conference.

The Cincinnati-based supermarket chain, whose $25-billion proposed merger with rival Albertsons (NYSE:ACI) was terminated after courts blocked the deal last month, said in a statement it hoped the settlement funds would be used to combat opioid abuse in Kentucky.

The company did not admit wrongdoing as part of the settlement and Kroger called the claims that it did not have internal training or guardrails around filling prescriptions for opioids “patently false.”

According to the settlement agreement, Kentucky received a substantial premium above what it would have received had it joined the earlier broader settlement with Kroger. Had it done so, Kentucky would have recovered $66.6 million.

Drug manufacturers, distributors, pharmacy operators and others have agreed to pay about $50 billion to resolve lawsuits and investigations by states and local governments over their roles in the drug-overdose epidemic.

Nearly 727,000 people in the U.S. died from opioid overdoses from 1999 to 2022, according to the U.S. Centers for Disease Control and Prevention.

This post appeared first on investing.com

You May Also Like

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 balanceandcharge.com

Exit mobile version